Ranibizumab is an anti-neovascularization agent used to treat eye diseases that cause vision impairment, such as age-related macular degeneration and diabetic macular edema. It works by inhibiting vascular endothelial growth factor A (VEGF-A), preventing abnormal blood vessel growth in the retina. This action helps stabilize and improve vision in affected patients. In summary, Ranibizumab is crucial for managing retinal diseases and preserving eyesight.
Ranibizumab binds to VEGF-A, blocking its interaction with receptors on endothelial cells, thus inhibiting neovascularization and edema.